Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + camrelizumab + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RC48 + PD-1 + platinum-based is an investigational combination regimen consisting of disitamab vedotin (RC48), camrelizumab (a PD-1 inhibitor), and platinum-based chemotherapy. It is being evaluated as a first-line treatment for locally advanced or metastatic HER2-overexpressing (IHC2+/3+) esophageal squamous cell carcinoma (ESCC). Disitamab vedotin is a HER2-directed antibody-drug conjugate (ADC) that delivers the cytotoxic payload monomethyl auristatin E (MMAE) to HER2-expressing tumor cells. Camrelizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, designed to restore T-cell antitumor activity. Platinum-based chemotherapy agents (such as cisplatin or carboplatin) act as DNA-damaging agents to inhibit tumor cell replication. This triplet regimen aims to leverage the synergistic effects of targeted cytotoxicity, immune checkpoint inhibition, and traditional chemotherapy.
- Other names
- RC48 + camrelizumab + platinum-based chemotherapydisitamab vedotin + camrelizumab + platinum
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + camrelizumab + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + camrelizumab + platinum-based chemotherapy.